ArticleMedicine2026
Association between hemoglobin glycation index and new-onset diabetes mellitus in individuals with chronic liver disease: Findings from a prospective cohort study using CHARLS data.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hemoglobin glycation index (HGI), which measures the difference between observed and predicted glycated hemoglobin, is strongly associated with diabetic complications. However, its relationship with new-onset diabetes in patients with chronic liver disease (CLD) remains unexplored. This study aimed to investigate this association using data from the China Health and Retirement Longitudinal Study database. This study included 329 participants aged ≥45 years with CLD from the China Health and Retirement Longitudinal Study database. HGI was calculated as glycated hemoglobin - (0.013 × fasting plasma glucose + 4.804). Based on baseline HGI levels, participants were categorized into 3 groups (Q1-Q3). The primary endpoint was the occurrence of new-onset diabetes mellitus events. The Kaplan-Meier curves, multivariable Cox proportional hazards models, and restricted cubic spline analysis were applied to explore the association between baseline HGI levels and the risk of diabetes mellitus incidence among individuals with CLD. In the adjusted multivariable Cox regression analysis, HGI was significantly associated with a 53% increased risk of diabetes (hazard ratio = 1.53, 95% confidence interval: 1.17-1.99, P = .002). The Kaplan-Meier curve analysis revealed a significant difference in the occurrence of diabetes mellitus among the HGI groups. Significant risk thresholds were identified at HGI = -0.94, beyond which diabetes mellitus risk increased substantially. Stratified and interaction analyses confirmed the stability of this association. An increase in baseline HGI levels was significantly associated with the risk of diabetes mellitus in individuals with CLD. HGI can be used as a potential indicator for predicting the long-term risk of diabetes incidence in such patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.